How Hyderabad Pharma Companies Find B2B Buyers: A Practical Guide

• 16 sourcing meetings with US formulation companies for an Indian API manufacturer, with 39 positive replies (Source: case study)

• ₹48 lakh in potential pipeline for a contract pharma manufacturer, from 19 qualified buyer conversations (Source: case study)

• Within 18 days campaigns go live, with first qualified buyer conversations in 3 to 5 weeks for most pharma clients (Source: Myntmore Benchmark Report)

The short answer

Most pharma companies in Hyderabad find new B2B buyers through exhibitions, referrals and existing customers. That builds strong relationships, but new business arrives unevenly: busy after a trade show, quiet in between.

The companies that grow more predictably add outbound. They build a list of companies with a current sourcing need, contact the named people who own that decision, keep every claim factual and approved, and hand interested buyers to their technical team quickly. This guide covers each step, with results from real pharma campaigns.

Why exhibitions and referrals are not enough

Hyderabad has one of India's largest concentrations of API, formulation and contract manufacturing companies, along with the biotech and life-sciences companies around Genome Valley. That density cuts both ways. Buyers know the city's reputation, but they also hear from many suppliers with similar capabilities.

Exhibitions and referrals share two weaknesses:

• Timing: they bring buyers on the calendar's schedule, not when a buyer is actually evaluating a new supplier.

• Reach: they mostly surface people you could already meet. They rarely get you to the sourcing head at a company that has never heard of you.

Several companies we have worked with described the same pattern. A packaging manufacturer relied on exhibitions, existing customers and offline introductions. A nutraceutical maker found most opportunities through referrals and exhibitions, which made business development inconsistent. An API supplier struggled to get past procurement gatekeepers at all.

Who to target, by what you sell

The most common mistake is contacting general business addresses or whoever has the most senior title. Pharma purchases are owned by specific roles, and they differ by what you sell.

The clinical research firm in our case studies is a good example of why this matters. Its outreach had been reaching general business contacts rather than the teams responsible for research partnerships. Once it was aimed at clinical operations and outsourcing stakeholders, it produced 14 high-intent meetings and one enterprise pilot under discussion.

Find the companies with a current need

A list of every pharma company in a country is not a prospect list. The sales team at one Indian API manufacturer had exactly that: a broad list, and no way to tell which companies had a relevant sourcing requirement right now.

The fix was to map only US formulation companies whose product portfolios used the client's APIs, then open with one specific question about whether they were evaluating a second source. From 150 target companies, that campaign produced 39 positive replies, 16 meetings held and 5 requests for technical evaluation. Read the full case study.

The same principle applies at home. Useful signals that a company may need a new supplier or partner include:

• Portfolio fit: they make or sell products that use what you supply.

• Expansion: a new product launch, a new market or a new facility.

• Supply risk: a reason to qualify a second source for an input they already buy.

• Partner search: a company entering a market where it needs local distribution.

What to say: factual, approved and specific

Pharma buyers read claims carefully, and an overstated one ends the conversation. The rules we follow in every pharma campaign:

1. 1

   Use only approved claims. State the certifications, dosage forms, capacity and documentation you actually hold, in wording your team has signed off. Make no regulatory claims on your behalf.

2. 2

   Open with one specific question, not a capability brochure. "Are you evaluating a second source for this API?" gets more replies than a list of everything you make.

3. 3

   Offer a technical conversation as the next step, with your own team, rather than pushing for a sale. The packaging manufacturer's follow-ups were designed this way, to start technical discussions instead of asking for an order.

4. 4

   Route compliance questions to your team. Anything a buyer asks about regulation or quality systems goes straight to the people qualified to answer.

5. 5

   Keep confidential material behind an NDA. In a licensing campaign we ran in Singapore, first contact used a non-confidential product summary, and the client handled confidentiality agreements once a discussion progressed.

On data protection, the rules depend on where your buyers are: GDPR in Europe, CAN-SPAM in the US and the DPDP Act in India. Our cold email compliance guide covers all three.

Selling from Hyderabad into export markets

Export campaigns follow the same targeting logic, with a few changes. These are from real campaigns for Indian pharma companies:

• United States: an API manufacturer reached procurement, sourcing and supply chain leaders at formulation companies, opening with a question about second-source evaluation. 16 sourcing meetings held.

• France: a tablet and capsule manufacturer reached sourcing and external manufacturing leaders with messages in French and English. 18 buyer meetings and 6 requests for quotation.

• UAE: a finished-formulation company looking for a distributor approached owners and business development heads at distributors and importers. 12 partner meetings and 3 companies shortlisted.

• Singapore: a specialty pharma developer offered two products for licensing to companies with a matching portfolio. 10 licensing meetings and 4 portfolio reviews under NDA.

• United Kingdom: a UK pharma company went from 3 to 20+ qualified meetings a month with a 35% positive response rate.

In the four campaigns where we publish the numbers, the list was small and specific: 45 to 150 target companies, not thousands. Precision is what made the reply rates possible.

What results to expect, and when

Pharma sales take longer than most B2B sales, and it helps to know the sequence in advance:

• Within 18 days: campaigns go live, once the target list, sending setup and approved copy are ready.

• Weeks 3 to 5: the first qualified buyer conversations take place.

• After that: buyers ask for documentation, samples, audits or technical reviews before quotations. That is normal progress, not a stalled deal.

The results from our domestic pharma work show what a few months of consistent outreach can produce:

• A contract manufacturer reached ₹48 lakh in potential pipeline from 19 qualified buyer conversations, with 6 opportunities in commercial evaluation.

• A nutraceutical manufacturer booked 22 qualified meetings in 90 days with distributors and private-label brands.

• A packaging manufacturer generated 26 warm leads, 5 of which moved to proposal discussions.

These are real engagements. Client names are withheld, and they are not all Hyderabad companies.

A 30-day starting plan

1. 1

   Week 1: pick one product line and one market. Write down which role owns the buying decision there, using the table above.

2. 2

   Week 1 to 2: build a list of 50 to 150 companies with a real portfolio fit. Agree the exact claims you are allowed to make, and set up separate sending domains.

3. 3

   Week 2: write a short sequence that opens with one specific question and offers a technical conversation as the next step.

4. 4

   Week 3: go live. Route every reply to one named person, and every compliance or quality question to your technical team.

5. 5

   Week 4: read every reply. If buyers say the timing is wrong, note when to come back. If they say the fit is wrong, fix the list before the copy.

If you would rather have this run for you, see how we work as a B2B lead generation company in Hyderabad, or read more about lead generation for pharma companies.